NCT04346628View on ClinicalTrials.gov

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

July 12, 2020

Primary Completion Date

April 16, 2021

Study Completion Date

April 16, 2021

Conditions
Sars-CoV2COVID-19
Interventions
DRUG

Favipiravir

Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).

DRUG

Placebo

Placebo to match favipiravir administered orally through day 10.

OTHER

Standard of care treatment

Standard of care treatment for COVID-19 infection

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04346628 - Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19 | Biotech Hunter | Biotech Hunter